# Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

> **NCT04513158** · PHASE2 · TERMINATED · sponsor: **Joseph M. Flynn, D.O., MPH** · enrollment: 2 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Convalescent Plasma

## Key facts

- **NCT ID:** NCT04513158
- **Lead sponsor:** Joseph M. Flynn, D.O., MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-14
- **Primary completion:** 2021-04-28
- **Final completion:** 2021-04-28
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Newly reported data at the time indicated that alternative therapies were more effective than CP for early treatment of high-risk patients with COVID-19.
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04513158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04513158, "Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04513158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*